In addition to more than 200 commercial human tumor cell lines, we currently have 80 proprietary cell lines derived from our PDX models, each with selected clinical data and comprehensive molecular data for the originating tumor, and which have been characterized by their sensitivity for up to 240 reference agents.

By using cell lines derived from our portfolio of PDX models, we retain characteristics such as expression and mutation profiles, which enables us to offer “matched pairs” of xenografts and corresponding cell lines. This allows you to use the same models for in vitro, ex vivo and in vivo efficacy studies.

We offer fixed screening panels for the most cost- and time-efficient studies such as:

  • Solid tumor histotypes
  • Hematological cell lines
  • Asian cancer cell lines

We also offer customized panels of up to 100 cell types.

Our 2D assays can be used in a variety of ways:

  • Assessment of potency and selectivity
  • Identification of mode of action via COMPARE analysis
  • Administration of combination studies
  • Analysis of multidrug resistance

You may also be interested in...

Cancer cell

Featured Story

As head of the Tumor Biology Modeling Lab, Julia Schüler, PhD, DVM, brings a breadth of experience and a plan to improve clinical success rates of our clients' oncology discovery programs.

Webinar Replay

View our recent webinar on cost- and time-effective methods of determining the most appropriate in vivo models for your oncology preclinical program.

Syngeneic Models

Charles River offers syngeneic mouse models suitable for the evaluation of immunobiological-based therapies.

logo screenshot

Charles River’s Entire Discovery Portfolio

Charles River offers the most comprehensive drug discovery service portfolio in the industry, supported by scientific excellence across major therapeutic areas and target classes.